3期ALSYMPCA试验中镭-223治疗相关碱性磷酸酶、乳酸脱氢酶和前列腺特异性抗原动态变化的探索性分析
基于3期ALSYMPCA试验(镭-223组N=614,安慰剂组N=307)的探索性分析,评估基线变量预后价值及生物标志物动态变化与总生存的关系。结果显示基线ECOG体能状态、总碱性磷酸酶(tALP)、乳酸脱氢酶(LDH)、前列腺特异性抗原(PSA)与总生存相关(P≤0.0003);镭-223组tALP自基线下降出现于开始治疗后4周内,第12周时87%镭-223组和23%安慰剂组患者tALP下降(P<0.001)。第12周tALP或LDH下降与更长总生存相关,但未达统计学替代终点要求。
要点
- 基线ECOG体能状态、tALP、LDH和PSA与CRPC骨转移患者总生存相关(P≤0.0003)。
- 镭-223组第12周tALP下降者占87%,安慰剂组占23%(P<0.001);LDH下降者分别占51%和34%(P=0.003)。
- 第12周tALP或LDH下降与更长总生存相关,但未满足统计学替代终点要求。
核心结论
- 镭-223治疗开始后4周内即可出现显著的tALP下降(对比安慰剂);第12周tALP或LDH下降与更长总生存相关,但未达统计学替代终点要求。
- 镭-223治疗期间tALP和LDH的动态变化可能有助于监测,但不作为生存的替代指标。
研究设计与样本
- 3期ALSYMPCA试验的探索性分析,纳入CRPC伴症状性骨转移患者,镭-223组N=614,安慰剂组N=307(意向治疗人群)。
- 采用Cox模型评估基线变量的预后潜力;评估试验期间生物标志物自基线的百分比变化,以及基线至第12周的变化与总生存的关联及替代性。
主要发现
- 基线ECOG体能状态、tALP、LDH和PSA与总生存相关(P≤0.0003)。
- tALP自基线下降出现于开始镭-223治疗后4周内;第12周时87%镭-223组和23%安慰剂组患者tALP下降(P<0.001)。
- LDH下降者镭-223组51% vs 安慰剂组34%(P=0.003);PSA下降者镭-223组27% vs 安慰剂组14%(P=0.160)。
- tALP自基线平均变化:镭-223组下降32.2%,安慰剂组升高37.2%。
- 镭-223组中自基线至第12周tALP下降(第12周后至少3周确认)的患者较无确认tALP下降者死亡风险降低55%(HR=0.45;95%CI 0.34-0.61)。
关键数值与推荐
- 第12周tALP、LDH和PSA自基线变化作为总生存替代标志物的比例治疗效应(PTE)值分别为0.34(95%CI 0-0.746)、0.07(95%CI 0-0.211)和0(95%CI 0-0.082)。
临床怎么用
- 原文结论指出镭-223治疗期间tALP和LDH的动态变化可能有助于监测,但不作为生存的替代指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baseline clinical variables are prognostic for overall survival (OS) in patients with castration-resistant prostate cancer (CRPC). Their prognostic and predictive value with agents targeting bone metastases, such as radium-223, is not established. PATIENTS AND METHODS: The radium-223 ALSYMPCA trial enrolled patients with CRPC and symptomatic bone metastases. Prognostic potential of baseline variables was assessed using Cox models. Percentage changes in biomarker levels from baseline were evaluated during the trial period; changes from baseline to week 12 were evaluated for association with OS and surrogacy. RESULTS: Eastern Cooperative Oncology Group performance status, total alkaline phosphatase (tALP), lactate dehydrogenase (LDH), and prostate-specific antigen (PSA) at baseline were associated with OS (P ≤ 0.0003) in the intent-to-treat population (radium-223, N = 614; placebo, N = 307). tALP declined from baseline within 4 weeks after beginning radium-223, by week 12 declining in 87% of radium-223 and 23% of placebo patients (P < 0.001). LDH declined in 51% and 34% (P = 0.003), whereas PSA declined in 27% and 14% (P = 0.160). Mean tALP change from baseline was 32.2% decrease with radium-223 and 37.2% increase with placebo. Radium-223 patients with tALP decline from baseline to week 12 (confirmed ≥3 weeks from week 12) had 55% lower risk of death (hazard ratio = 0.45; 95% CI 0.34-0.61) versus those with no confirmed tALP decline. Proportional treatment effect (PTE) values for tALP, LDH, and PSA changes from baseline at week 12 as OS surrogate markers were 0.34 (95% CI: 0-0.746), 0.07 (95% CI: 0-0.211), and 0 (95% CI: 0-0.082), respectively. CONCLUSIONS: Significant tALP declines (versus placebo) occurred as early as 4 weeks after beginning radium-223 therapy. tALP or LDH declines at 12 weeks correlated with longer OS, but did not meet statistical surrogacy requirements. Dynamic changes in tALP and LDH during radium-223 treatments may be useful to monitor, but do not serve as surrogates for survival.
引用
- Sartor O, Coleman RE, Nilsson S, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017. PMID: 28453701. doi:10.1093/annonc/mdx044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。